International reference: 2 US FDA recalls for this ingredient

CGMP Deviations: Products are being recalled due to an out of specification total aerobic microbial count in a water sample. (sennosides)

Subpotent Drug: Formulated amount of sennosides component is less than labelled claim. (sennosides)

US-market enforcement records (OpenFDA), shown for reference - not specific to this product in South Africa.

Registered South Africa · SAHPRA

PROSENNA

SENNOSIDES B

59/11.5/0178

What it does

Sennosides are natural compounds used to relieve constipation by stimulating bowel movements.

Commonly used for: constipation, irregular bowel movements

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
59/11.5/0178
Registration date
2026/02/24
Expiry date
-
Status
Registered
Active ingredient
SENNOSIDES B
Dosage form
-
Strength
-
Pack size
-
Therapeutic class
-
Manufacturer / MAH
-
Applicant / LTR
Unimed Healthcare (Pty) Ltd
Country of origin
-

Source: South African Health Products Regulatory Authority · fetched 2026-04-15 21:30:22 · updated 2026-10-21 04:02:22

Disclaimer: This information is sourced from South African Health Products Regulatory Authority (South Africa). Always consult a qualified healthcare professional before using any medication.

About this medicine

Sennosides are natural compounds used to relieve constipation by stimulating bowel movements.

What it treats

  • constipation
  • irregular bowel movements

How it works

Sennosides work by increasing the movement in the intestines, helping to push waste out of the body.

Who it's for

Sennosides are suitable for adults and children over the age of 12 who need help with constipation.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: sennosides

BNF-referenced

Sennosides are natural anthraquinone glycosides derived from the Senna plant. They are primarily used as a stimulant laxative to relieve constipation. The active components, sennoside A and B, are metabolized by gut bacteria into rheinanthrone, which exerts laxative effects by influencing water absorption in the intestines and stimulating intestinal motility.

Indications

  • Constipation
  • Bowel preparation for diagnostic procedures

Dosage

Children: For children aged 6 to 12 years, the recommended dose is 5 to 10 mg at bedtime. For those over 12 years, the adult dosage applies. Always refer to the BNF for Children for specific dosing guidance.

Adults: The usual adult dose for constipation is 7.5 to 15 mg of sennosides taken at bedtime. For bowel preparation, higher doses may be required as directed by a healthcare provider.

Mechanism of action

Sennoside A and B are metabolized by gut bacteria into rheinanthrone, which increases cyclooxygenase 2 (COX2) expression in macrophage cells, leading to elevated levels of prostaglandin E2 (PGE2). This increase in PGE2 decreases aquaporin 3 expression in the mucosal epithelial cells of the large intestine, reducing water reabsorption and increasing fecal water content, resulting in a laxative effect. Rheinanthrone also stimulates peristalsis in the large intestine, although the precise mechanism is not fully understood. Additionally, another metabolite, rhein, may activate submucosal acetylcholinergic neurons, enhancing chloride and prostaglandin secretion, thereby promoting water influx into the intestinal lumen.

Pharmacodynamics

Sennosides stimulate intestinal peristalsis and enhance fecal water content, which collectively increases the motility of feces through the large intestine, facilitating bowel movements.

Pharmacokinetics

Sennosides are absorbed in the intestine and then metabolized by gut bacteria into active metabolites. The onset of action is typically within 6 to 12 hours after oral administration, depending on the formulation. The metabolites, particularly rheinanthrone, exert their effects locally in the large intestine, with minimal systemic absorption.

Contra-indications

  • Intestinal obstruction
  • Severe dehydration
  • Appendicitis
  • Abdominal pain of unknown origin
  • Ulcerative colitis
  • Crohn's disease
  • Severe abdominal conditions

Adverse effects

  • Abdominal cramps
  • Diarrhea
  • Nausea
  • Vomiting
  • Electrolyte imbalances
  • Discoloration of urine

Interactions

  • May enhance the effects of other laxatives
  • May reduce the effectiveness of certain medications due to altered gastrointestinal motility

Precautions

  • Use with caution in patients with known gastrointestinal disorders
  • Long-term use may lead to dependence
  • Monitor for signs of electrolyte imbalance
  • Not recommended for use in children under 12 years without medical advice

Pregnancy

Use during pregnancy should be avoided unless specifically advised by a healthcare provider, as safety has not been established.

Breast-feeding

Limited data available; caution is advised as sennosides may be excreted in breast milk.

Storage

Store in a cool, dry place, away from direct sunlight and out of reach of children.

Formulations

  • Oral tablets
  • Syrup
  • Powder for oral solution

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: sennosides

PubChem CID 5199

Molecular formula: C42H38O20

Mechanism of action

Sennoside A and B, the components of senna, are metabolized by gut bacteria into the active metabolite rheinanthrone [DB13175]. Rheinanthrone [DB13175] appears to increase cyclooxegenase 2 (COX2) expression in macrophage cells leading to an increase in prostaglandin E2 (PGE2). This increase in PGE2 is associated with a decrease in aquaporin 3 expression in mucosal epithelial cells of the large intestine. A decrease in aquaporin 3 expression likely produces the laxative effect by restricting water reabsorption by the large intestine thereby increasing fecal water content. The exact mechanism by which rheinanthrone increases COX2 expression is unknown. Rheinanthrone [DB13175] also stimulates peristalsis in the large intestine although the mechanism behind this effect is unknown. Rhein [DB13174], another active metabolite is thought to excite submucosal acetylcholinergic neurons resulting in increased chloride and prostaglandin secretion. The movement of chloride ions into the large intestine would also help to draw water into the lumen.

Pharmacodynamics

Senna stimulates peristalsis and increases fecal water content to increase motility of feces through the large intestine.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.